BI-638683

BI-638683 is a small molecule drug developed by Boehringer Ingelheim as a selective antagonist of the C-C chemokine receptor type 1 (CCR1). Its primary mechanism of action is to inhibit CCR1, which plays a role in inflammatory processes. The drug was investigated for potential oral treatment of rheumatoid arthritis. In clinical studies, BI-638683 demonstrated good safety and tolerability profiles in healthy male volunteers, with no serious or severe adverse events reported. Pharmacodynamic data showed dose-dependent inhibition of CCR1-dependent marker gene expression and robust target engagement at higher doses. The compound reached maximal inhibition of mRNA expression for several CCR1-dependent genes at specific dosing levels[2][3][4]. Development appears to have reached Phase I clinical trials.

Other names

295298-26-8